FUJIFILM Completes £400M UK Teesside CDMO Expansion, Accelerating Bioprocess Innovation and Cell Product Diversification

Fujifilm Japan

Overview

FUJIFILM announced significant life sciences advancements at BIO 2026, notably completing a £400 million investment in its UK Teesside manufacturing facility, making it the largest single-use CDMO site in the country. This dramatically enhances biopharmaceutical manufacturing capacity. Furthermore, FUJIFILM Biotechnologies is driving bioprocessing innovation with its MaruX continuous processing platform, while expanding its iCell® series with new iPSC-derived cell products like intestinal epithelial cells, GFP microglia, and cardio-spheroids, increasing diversity for research tools.

In Depth

Key Finding: FUJIFILM Completes UK Teesside CDMO Expansion, Bolstering Bioprocess and Cell Product Portfolios with £400M Investment

FUJIFILM announced strategic advancements in its life sciences division at BIO 2026. Most notably, the company has completed a substantial expansion project with a £400 million investment in its manufacturing facility in Teesside, UK. This initiative has transformed the site into the UK’s largest single-use Contract Development and Manufacturing Organization (CDMO) facility, dramatically enhancing biopharmaceutical manufacturing capabilities. This investment underscores FUJIFILM’s strong commitment to meeting the growing global demand for biopharmaceuticals and providing high-quality manufacturing services to its clients.

Technical & Clinical Details: Expanding Manufacturing Infrastructure and Innovative Platforms

• UK Teesside Facility Expansion: The newly expanded facility is engineered with state-of-the-art single-use bioreactor systems and associated downstream processing technologies, designed to accommodate large-scale cell culture and purification. The adoption of single-use technology significantly enhances manufacturing flexibility and efficiency by reducing the risk of cross-contamination and enabling rapid changeovers between processes. This capacity allows FUJIFILM to address a wide range of biopharmaceutical manufacturing needs, including monoclonal antibodies, recombinant proteins, and cell and gene therapy products.
• New Research Facilities: FUJIFILM has also established the Bioprocess Innovation Centre UK and a new Quality Control (QC) lab in Hillerød, Denmark. These facilities will support the optimization of bioprocess development, validation of analytical methods, and stringent control of product quality, fostering the rapid introduction of innovative technologies and compliance with global quality standards.
• MaruX Continuous Processing Platform: FUJIFILM Biotechnologies is enhancing bioprocessing innovation through the introduction of MaruX, an agile and fully integrated continuous processing platform. Continuous processing offers the potential for increased productivity, reduced costs, and a smaller manufacturing footprint compared to traditional batch processing, and is expected to become a mainstream approach in future biopharmaceutical manufacturing.
• Expansion of iCell® Product Line: FUJIFILM Cellular Dynamics (FCDI) has broadened its iCell® series by adding new iPSC (induced pluripotent stem cell)-derived cell products, including iCell® Intestinal Epithelial Cells, iCell® GFP Microglia, and iCell® CardioSpheres. These products provide more physiologically relevant in vitro models for drug discovery research, disease modeling, and toxicity testing, thereby contributing to the more efficient development of pharmaceuticals.

Background & Industry Context: Global Demand for Biopharmaceutical Manufacturing Capacity

The biopharmaceutical market is expanding rapidly due to its effectiveness in treating diseases such as cancer, autoimmune disorders, and rare conditions. This growth has led to an increased demand for manufacturing capacity, particularly for complex biologics which require specialized technologies and facilities. CDMOs are vital partners for pharmaceutical companies to efficiently leverage these capabilities. FUJIFILM’s investment is a strategic move to address this global demand.

Future Outlook: Strengthening Leadership in Biopharmaceuticals and Regenerative Medicine

These strategic investments and product expansions by FUJIFILM indicate the company’s commitment to further strengthen its leadership in biopharmaceutical manufacturing and regenerative medicine. Through the provision of innovative manufacturing technologies and diverse iPSC-derived cell products, FUJIFILM is expected to contribute to accelerating drug development and offering new treatments to patients. By embracing digital technologies and advanced automation, the company is poised to establish future biomanufacturing standards and achieve sustainable growth.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime